Get the Stockscreener App
0.3801
0.11%
0.0004
Pre-market:
.37
-0.0101
-2.66%
Theriva Biologics Inc stock is traded at $0.3801, with a volume of 2.37M.
It is up +0.11% in the last 24 hours and up +65.33% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.3797
Open:
$0.3684
24h Volume:
2.37M
Relative Volume:
0.10
Market Cap:
$17.44M
Revenue:
-
Net Income/Loss:
$-23.74M
P/E Ratio:
-0.0942
EPS:
-4.0366
Net Cash Flow:
$-16.70M
1W Performance:
+6.35%
1M Performance:
+65.33%
6M Performance:
+28.37%
1Y Performance:
-72.75%
1-Day Range:
$0.366
$0.3801
1-Week Range:
$0.3257
$0.3899
52-Week Range:
$0.1628
$1.45
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.3801 | 17.44M | 0 | -23.74M | -16.70M | -4.0366 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com
Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan
Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan
Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan
TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
MSN Money - MSN
Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey
Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Why is Theriva stock gaining Monday? - MSN
symbol__ Stock Quote Price and Forecast - CNN
TOVX Should I Buy - Intellectia AI
Press Releases about Theriva Biologics, Inc. Common Stock (NYSE:TOVX) - FinancialContent
Theriva Biologics posts 34.6% EPS beat, no revenueMeet Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Theriva Biologics announces pricing of $7.5M public offering - MSN
Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenueBorrow Rate - Cổng thông tin điện tử tỉnh Lào Cai
TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment.Popular Trader Picks - Cổng thông tin điện tử Tỉnh Sơn La
Trending Stocks Today | Theriva Biologics Soars 67.92% Post-Market - 富途牛牛
BIOLASE Inc (BIOL) - Minichart
Theriva Biologics (NYSE: TOVX) asks shareholders to OK 16.18M warrant shares for $8.7M - Stock Titan
$Theriva Biologics (TOVX.US)$ keep loading on each pullback - Moomoo
Theriva Biologics stock surges on AACR cancer trial data - Investing.com
Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR - MEXC Exchange
Theriva Biologics stock surges on AACR cancer trial data By Investing.com - Investing.com UK
$Theriva Biologics (TOVX.US)$ it might be a miracle - Moomoo
Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20IPO Watch - Cổng thông tin điện tử tỉnh Lào Cai
Why Is Theriva Stock Gaining Monday? - Benzinga
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Data from AACR - MoneyCheck
Theriva Biologics (TOVX) Shares Soar 63% on Promising Pancreatic Cancer Trial Results - parameter.io
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Results - Blockonomi
$Theriva Biologics (TOVX.US)$ added more to squeeze 🤞🏼🥳 - Moomoo
Theriva Biologics Presents Positive VIRAGE Phase 2b Clinical Trial Data of VCN-01 for Metastatic Pancreatic Cancer at AACR 2026 - Minichart
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 - GlobeNewswire Inc.
Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC - GuruFocus
$Theriva Biologics (TOVX.US)$ sell too fast wow - Moomoo
Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data - TipRanks
[8-K] Theriva Biologics, Inc. Reports Material Event - Stock Titan
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - GlobeNewswire
CEO Moves: Is Theriva Biologics Inc subject to activist investor interest2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart
Theriva Biologics to reschedule stockholder meeting after lack of quorum By Investing.com - Investing.com Australia
Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com
Resistance Check: Is Theriva Biologics Inc in a long term uptrend2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Theriva Biologics Faces Delays in Warrant Approval Meeting - TipRanks
Theriva Bi Called Special Meeting Fails to Reach Quorum; Will Re‑call Meeting to Seek Approval for 16.18M Warrant Shares - TradingView
Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Cap:
|
Volume (24h):